title: Long-term efficacy and tolerability of rizatriptan wafers in migraine.
abstract: BACKGROUND
  Rizatriptan is a selective 5-HT1B/1D receptor agonist for the acute treatment of migraine. It is available in a unique wafer formulation that dissolves rapidly in the mouth and can be taken without liquids, thereby offering patients a very convenient way to take treatment.
  
  
  OBJECTIVE
  To investigate the long-term efficacy of rizatriptan 10-mg and 5-mg wafers in migraineurs.
  
  
  METHODS
  19 headache clinics in 5 countries.
  
  
  METHODS
  458 patients diagnosed with migraine according to International Headache Society criteria.
  
  
  METHODS
  6-month, open-label, extension, which followed a double-blind, placebo-controlled study.
  
  
  METHODS
  Patients were randomly assigned to 1 of 3 treatments for moderate or severe migraines: rizatriptan 10-mg wafer, rizatriptan 5-mg wafer, or "standard care" (usual migraine treatment -- eg, nonsteroidal anti-inflammatory drugs [NSAIDs], analgesics, other triptans). Patients randomized to rizatriptan were blinded to the dose.
  
  
  METHODS
  Headache severity (none, mild, moderate, severe) and adverse events were recorded on a diary card.
  
  
  RESULTS
  181 patients treated 3393 attacks with rizatriptan 10-mg wafer, 191 treated 3254 attacks with rizatriptan 5-mg wafer, and 86 treated 1582 attacks with standard care. The median number of treated attacks per patient was 16 for rizatriptan 10-mg wafer, 13 for rizatriptan 5-mg wafer, and 14 for standard care. The median patient on rizatriptan 10-mg wafer reported pain relief at 2 hours (reduction of headache from moderate or severe at baseline to mild or none) in 82% of attacks, vs 73% of attacks for standard care (odds ratio [95% confidence interval] = 1.63 [1.14, 2.34], P <.01) and 72% of attacks for rizatriptan 5-mg wafer (OR [95% CI] = 1.60 [1.23, 2.08], P <.001). The median patient on rizatriptan 10-mg wafer was pain free at 2 hours in 46% of attacks, vs 30% of attacks for standard care (OR [95% CI] = 1.50 [1.06, 2.12], P <.05) and 25% of attacks for rizatriptan 5-mg wafer (OR [95% CI] = 1.93 [1.50, 2.49], P <.001). All treatments were generally well tolerated. Compared with standard care, rizatriptan 5-mg wafer was associated with fewer specific adverse events of asthenia/fatigue, back pain, nausea, pharyngeal discomfort, upper respiratory infection, and vomiting (P values <.05), and, compared with rizatriptan 10-mg wafer, fewer overall drug-related adverse events (P <.05).
  
  
  CONCLUSIONS
  Rizatriptan 10-mg wafer was more effective than standard care and rizatriptan 5-mg wafer for treating intermittent moderate or severe migraine attacks occurring over periods of up to 6 months. Rizatriptan wafers were well tolerated.
authors.affiliation: Headache Care Center, Springfield, Missouri, USA.
authors.forename: R
authors.initials: R
authors.lastname: Cady
authors.forename: G
authors.initials: G
authors.lastname: Crawford
authors.forename: S
authors.initials: S
authors.lastname: Ahrens
authors.forename: D
authors.initials: D
authors.lastname: Hairwassers
authors.forename: A
authors.initials: A
authors.lastname: Getson
authors.forename: W H
authors.initials: WH
authors.lastname: Visser
authors.forename: C
authors.initials: C
authors.lastname: Lines
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D010147:Pain Measurement; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D014363:Tryptamines
chemical_list: D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan